Aeglea BioTherapeutics, Inc. (AGLE) EPS Estimated At $-0.41

October 13, 2018 - By Peter Kolinski

Analysts expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to report $-0.41 EPS on November, 6.They anticipate $0.07 EPS change or 14.58 % from last quarter’s $-0.48 EPS. After having $-0.46 EPS previously, Aeglea BioTherapeutics, Inc.’s analysts see -10.87 % EPS growth. The stock increased 0.11% or $0.01 during the last trading session, reaching $9.08. About 192,411 shares traded. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) has risen 96.03% since October 13, 2017 and is uptrending. It has outperformed by 80.41% the S&P500.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company has market cap of $200.50 million. The Company’s human enzymes are designed to degrade specific amino acids in the blood. It currently has negative earnings. The company's lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies.

More important recent Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) news were published by: which released: “Aeglea BioTherapeutics (AGLE) to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at ASHG” on October 10, 2018, also published article titled: “Key events next week – healthcare”, published: “Aeglea BioTherapeutics (AGLE) Announces FDA Granted Rare Pediatric Disease Designation to Pegzilarginase for …” on October 01, 2018. More interesting news about Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) was released by: and their article: “Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at …” with publication date: September 17, 2018.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.